Biotech Values

[biopearl]

Might be worth keeping an eye out for GERNs imetelstat, which target the MM stem cell and looks promising, just entering phase II studies. On another note, Dew kudos, and warm thanks for bringing MNTA into my life. I have lots of long term capital losses from gtcb to offset my gains but plan to hold both, I know I would never have seen daylight again without the MNTA guidance you provided and am now close to break even with lots of potential left for MNTA. For any old timers, the gtcb conference call is tomorrow under new management. Looks like the goats lost rounds one through 10 on the biogeneric vs biosimilar discussion. Regards, bp